Publications by authors named "Jeffrey Engelman"

Claim this Profile
S
Structural basis of DNA-dependent coactivator recruitment by the tuft cell master regulator POU2F3.
Aktan Alpsoy, Jonathan J Ipsaro, Damianos Skopelitis, Sujay Pal, Frank S Chung, Jeffrey A Engelman

Cell Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras.
Charles W Parry, Francesca Pellicano, Alexander W Schüttelkopf, Kim S Beyer, Justin Bower, Jeffrey Engelman

J Med Chem· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.
Slavica Dimitrieva, Jon M Harrison, Jonathan Chang, Michelle Piquet, Mari Mino-Kenudson, Jeffrey A Engelman

Cancer Res Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.
Jennifer L Cotton, Javier Estrada Diez, Vivek Sagar, Julie Chen, Michelle Piquet, Jeffrey A Engelman

Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Jeffrey A Engelman

Nature· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A landscape of response to drug combinations in non-small cell lung cancer.
Nishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, Adam A Friedman, Arnaud Amzallag, Jeffrey A Engelman

Nat Commun· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Ralph Tiedt, Frederick J King, Christelle Stamm, Matthew J Niederst, Scott Delach, Jeffrey A Engelman

Cell Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.
Simone Bonazzi, Eva d'Hennezel, Rohan E J Beckwith, Lei Xu, Aleem Fazal, Jeffrey A Engelman

Cell Chem Biol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retraction Note: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Michela Garofalo, Giulia Romano, Gianpiero Di Leva, Gerard Nuovo, Young-Jun Jeon, Jeffrey A Engelman

Nat Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
Haichuan Hu, Zofia Piotrowska, Patricia J Hare, Huidong Chen, Hillary E Mulvey, Jeffrey A Engelman

Cancer Cell· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The present and future of PI3K inhibitors for cancer therapy.
Pau Castel, Eneda Toska, Jeffrey A Engelman, Maurizio Scaltriti

Nat Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.
Bernard Pereira, Christopher T Chen, Lipika Goyal, Charlotte Walmsley, Christopher J Pinto, Jeffrey A Engelman

Nat Commun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Kelli-Ann Monaco, Scott Delach, Jing Yuan, Yuji Mishina, Paul Fordjour, Jeffrey A Engelman

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Chen Liu, Hengyu Lu, Hongyun Wang, Alice Loo, Xiamei Zhang, Jeffrey A Engelman

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
Ye Wang, Morvarid Mohseni, Angelo Grauel, Javier Estrada Diez, Wei Guan, Jeffrey A Engelman

Sci Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts.
Angelo L Grauel, Beverly Nguyen, David Ruddy, Tyler Laszewski, Stephanie Schwartz, Jeffrey A Engelman

Nat Commun· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
Adam C Palmer, Deborah Plana, Hui Gao, Joshua M Korn, Guizhi Yang, Jeffrey A Engelman

Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Carlotta Costa, Ye Wang, Amy Ly, Yasuyuki Hosono, Ellen Murchie, Jeffrey A Engelman

Cancer Discov· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.
Hengyu Lu, Chen Liu, Hung Huynh, Thi Bich Uyen Le, Matthew J LaMarche, Jeffrey A Engelman

Oncotarget· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Jeffrey A Engelman

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Sana Raoof, Iain J Mulford, Heidie Frisco-Cabanos, Varuna Nangia, Daria Timonina, Jeffrey A Engelman

Oncogene· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas Manuel Dunkl, Jeffrey A Engelman

Mol Cancer Ther· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
Lynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, Patrick Dinkelborg, Heike Pfäffle, Jeffrey A Engelman

Cell Rep· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263.
Anahita Dastur, AHyun Choi, Carlotta Costa, Xunqin Yin, August Williams, Jeffrey A Engelman

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Elena J Orlando, Xia Han, Catherine Tribouley, Patricia A Wood, Rebecca J Leary, Jeffrey A Engelman

Nat Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis